Home › Therapeutic areas › Antineoplastic antibiotics
Japan market screening · Therapeutic class
抗腫瘍性抗生物質製剤 · Japan Standard Commodity Classification
12 molecules in this class are marketed in Japan across 25 products. 1 of those products are not shipping normally today — 4.0% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Doxorubicin Hydrochlorideドキソルビシン塩酸塩 | 7 | 4 | 1 | |
| Epirubicin Hydrochlorideエピルビシン塩酸塩 | 4 | 2 | — | |
| Mitomycin CマイトマイシンＣ | 3 | 1 | — | |
| Amrubicin Hydrochlorideアムルビシン塩酸塩 | 2 | 1 | — | |
| Bleomycin Hydrochlorideブレオマイシン塩酸塩 | 2 | 1 | — | |
| Aclarubicin Hydrochlorideアクラルビシン塩酸塩 | 1 | 1 | — | |
| Actinomycin DアクチノマイシンＤ | 1 | 1 | — | |
| Bleomycin Sulfateブレオマイシン硫酸塩 | 1 | 1 | — | |
| Daunorubicin Hydrochlorideダウノルビシン塩酸塩 | 1 | 1 | — | |
| Gemtuzumab Ozogamicin (Genetical Recombination)ゲムツズマブオゾガマイシン（遺伝子組換え） | 1 | 1 | — | |
| Idarubicin Hydrochlorideイダルビシン塩酸塩 | 1 | 1 | — | |
| Inotuzumab Ozogamicin (Genetical Recombination)イノツズマブ オゾガマイシン（遺伝子組換え） | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).